Fidelity Investments
TRDA icon

Fidelity Investments’s Entrada Therapeutics TRDA Stock Holding History

Fidelity Investments’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16K Sell
2,169
-14,774
-87% -$142K ﹤0.01% 4745
2026
Q1 		$214K Buy
16,943
+121
+0.7% +$1.39K ﹤0.01% 3469
2025
Q4 		$173K Sell
16,822
-15,124
-47% -$127K ﹤0.01% 3501
2025
Q3 		$185K Sell
31,946
-464,183
-94% -$2.72M ﹤0.01% 3381
2025
Q2 		$3.33M Sell
496,129
-743,682
-60% -$5.98M ﹤0.01% 2309
2025
Q1 		$11.2M Sell
1,239,811
-160,105
-11% -$2M ﹤0.01% 1868
2024
Q4 		$24.2M Sell
1,399,916
-343,582
-20% -$6.22M ﹤0.01% 1657
2024
Q3 		$27.9M Sell
1,743,498
-85,667
-5% -$1.35M ﹤0.01% 1597
2024
Q2 		$26.1M Buy
1,829,165
+1,661,244
+989% +$23.6M ﹤0.01% 1555
2024
Q1 		$2.38M Sell
167,921
-367,602
-69% -$5.2M ﹤0.01% 2286
2023
Q4 		$8.08M Sell
535,523
-46,593
-8% -$690K ﹤0.01% 1924
2023
Q3 		$9.2M Buy
582,116
+179
+0% +$2.82K ﹤0.01% 1846
2023
Q2 		$8.81M Buy
581,937
+50,529
+10% +$696K ﹤0.01% 1905
2023
Q1 		$7.71M Buy
531,408
+27,497
+5% +$367K ﹤0.01% 1969
2022
Q4 		$6.81M Buy
503,911
+4
+0% +$70 ﹤0.01% 2030
2022
Q3 		$7.94M Sell
503,907
-441,001
-47% -$5.6M ﹤0.01% 1999
2022
Q2 		$11.5M Buy
944,908
+68,114
+8% +$517K ﹤0.01% 1905
2022
Q1 		$8.23M Buy
876,794
+590,994
+207% +$6.34M ﹤0.01% 2196
2021
Q4 		$4.89M Buy
+285,800
New +$6.93M ﹤0.01% 2370

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Fidelity Investments's TRDA Position: Q2 2026 in Review

Fidelity Investments reduced its Entrada Therapeutics (TRDA) stake by 87% in Q2 2026, selling an estimated $142K and leaving 2,169 shares worth $16K. The position accounts for ﹤0.01% of the portfolio, ranked #4745.

Fidelity Investments first reported a position in TRDA in Q4 2021 and has held it in 19 quarters since. The position peaked at $27.9M in Q3 2024. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Fidelity Investments held 2,169 shares of Entrada Therapeutics worth $16K as of Q2 2026.
  • Fidelity Investments sold 14,774 Entrada Therapeutics shares in Q2 2026, an estimated $142K.
  • Entrada Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #4745 holding.
  • Fidelity Investments first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • Fidelity Investments's Entrada Therapeutics position peaked at $27.9M in Q3 2024.
  • 129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.